Short‐Term, High‐Dose Fish Oil Supplementation Increases the Production of Omega‐3 Fatty Acid–Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA‐PAD I Trial)
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Background: Patients with peripheral artery disease ( PAD ) experience significant morbidity and mortality. The OMEGA ‐ PAD I Trial, a randomized, double‐blinded, placebo‐controlled trial, addressed the hypothesis that short‐duration, high‐dose n‐3 polyunsaturated fatty acids (n‐3 PUFA ) oral supplementation improves endothelial function and inflammation in PAD . Methods and Results: Eighty patients with stable claudication received 4.4 g of fish oil or placebo for 1 month. The primary end point was endothelial function as measured by brachial artery flow‐mediated vasodilation. Secondary end points included biomarkers of inflammation, n‐3 polyunsaturated fatty acids metabolome changes, lipid profile, and walking impairment questionnaires. Although there was a significant increase in FMD in the fish oil group following treatment (0.7±1.8% increase from baseline, P =0.04), this response was not different then the placebo group (0.6±2.5% increase from baseline, P =0.18; between‐group P =0.86) leading to a negative finding for the primary endpoint. There was, however, a significant reduction in triglycerides (fish oil: −34±46 mg/ dL , P <0.001; placebo −10±43 mg/ dL , P =0.20; between‐group differential P ‐value: 0.02), and an increase in the omega‐3 index of 4±1% ( P <0.001) in the fish oil group (placebo 0.1±0.9%, P =0.49; between‐group P <0.0001). We observed a significant increase in the production of pathway markers of specialized pro‐resolving mediators generated from n‐3 polyunsaturated fatty acids in the fish oil group. Conclusions: High‐dose, short‐duration fish oil supplementation did not lead to a different response in the primary end point of endothelial function between the treatment and placebo group, but improved serum triglycerides and increased the production of downstream n‐3 polyunsaturated fatty acids–derived products and mediators in patients with PAD . Clinical Trial Registration: URL : https://www.clinicaltrials.gov/ . Unique identifier: NCT 01310270.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
Kris-Etherton, P. M., Harris, W. S., & Appel, L. J. (2002) · Circulation · doi:10.1161/01.cir.0000038493.65177.94 · Cited by 3,707
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041 · cited 11×
“0.36, P = 0.003), which is consistent with shunting of lipoxygenase substrates from AA to EPA and DHA.”
BackgroundMethodResultInfluentialResolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932
Lichtenstein, A. H., Appel, L. J., Brands, M., Carnethon, M., Daniels, S., Franch, H. A., Franklin, B., Kris-Etherton, P., Harris, W. S., Howard, B., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.176158 · Cited by 2,705
Burr, M. L., Gilbert, J. F., Holliday, R. M., Elwood, P. C., Fehily, A. M., Rogers, S., Sweetnam, P. M., & Deadman, N. M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)90828-3 · Cited by 2,610
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650 · cited 1×
“27,65,66 In the future, it would be prudent to design studies that have suf fi ciently high n-3 PUFA dosing and duration to counteract the increased in fl ammatory state in PAD and to more accurately examine the nutrient ’ s clinical effects.”
BackgroundSerhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.8.1197 · Cited by 1,189 · cited 2×
“Resolvin E1 (RvE1), a downstream product and proresolving lipid mediator generated from 18-hydroperoxy-EPE, 43 was sparsely identi fi ed in the fi sh oil group, although there was no signi fi cant difference in the production of this short-lived and locally produced mediator throughout the duration of…”
BackgroundMaresins: Novel macrophage mediators with potent antiinflammatory and proresolving actions
Serhan, C. N., Yang, R., Martinod, K., Kasuga, K., Pillai, P. S., Porter, T. F., Oh, S. F., & Spite, M. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20081880 · Cited by 908
Self-citationResolvin D2 is a potent regulator of leukocytes and controls microbial sepsis
Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., & Serhan, C. N. (2009) · Nature · doi:10.1038/nature08541 · Cited by 695
Self-citationn–3 Fatty Acids in Patients with Multiple Cardiovascular Risk Factors
The Risk and Prevention Study Collaborative Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205409 · Cited by 510 · cited 3×
“6 4 [0 , 23 ] 0 [0 , 0] 0.”
Peripheral Arterial Disease: Morbidity and Mortality Implications
Golomb, B. A., Dang, T. T., & Criqui, M. H. (2006) · Circulation · doi:10.1161/circulationaha.105.593442 · Cited by 498 · cited 1×
“5,6,53 Despite available medical therapies, patients with PAD continue to have a higher risk of CV events compared to patients with coronary artery disease, 2,3 and this difference is thought to be related to increased systemic in fl ammation.”
BackgroundMcDermott, M. M., Ades, P., Guralnik, J. M., Dyer, A., Ferrucci, L., Liu, K., Nelson, M., Lloyd-Jones, D., Van Horn, L., Garside, D., et al. (2009) · JAMA · doi:10.1001/jama.2008.962 · Cited by 449
Merched, A. J., Ko, K., Gotlinger, K. H., Serhan, C. N., & Chan, L. (2008) · The FASEB Journal · doi:10.1096/fj.08-112201 · Cited by 414 · cited 1×
“27,55,64 Further longer-term studies will be required to determine whether SPM pathways are enriched as disease progression slows and vascular function improves and whether these changes precede changes in in fl ammatory biomarkers.”
BackgroundOmega‐3 Dietary Supplements and the Risk of Cardiovascular Events: A Systematic Review
Marik, P. E., & Varon, J. (2009) · Clinical Cardiology · doi:10.1002/clc.20604 · Cited by 328 · cited 1×
“15 In a recent review, our group observed that only a limited number of studies exist on the role of n-3 PUFA in PAD.”
BackgroundMas, E., Croft, K. D., Zahra, P., Barden, A., & Mori, T. A. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.190199 · Cited by 270 · cited 2×
“29,30,62 Thus, sparse detection of SPM end products in this study could also be related to defective bioconversion of intermediates into resolvins, protectins, and maresins.”
BackgroundHo, K. J., Spite, M., Owens, C. D., Lancero, H., Kroemer, A. H. K., Pande, R., Creager, M. A., Serhan, C. N., & Conte, M. S. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.091082 · Cited by 204
Self-citationOmega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., & Neal, B. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966168 · Cited by 201 · cited 1×
“LX B 4 0 [0 , 0] 0 [0 , 0] NA 68 3 90 [0 , 22 39 ] 0 [0 , 0] 0.”
Grenon, S. M., Vittinghoff, E., Owens, C. D., Conte, M. S., Whooley, M., & Cohen, B. E. (2013) · Vascular Medicine · doi:10.1177/1358863x13493825 · Cited by 169 · cited 1×
“Despite available medical therapies, patients with PAD continue to have a higher risk of CV events compared to patients with coronary artery disease,(2,3) and this difference is thought to be related to increased systemic inflammation.(1) There is an important unmet need to optimize medical management for patients wit…”
BackgroundSelf-citation
Cited by
Hahn, J., Cook, N. R., Alexander, E. K., Friedman, S., Walter, J., Bubes, V., Kotler, G., Lee, I.-M., Manson, J. E., & Costenbader, K. H. (2022) · BMJ · doi:10.1136/bmj-2021-066452 · Cited by 414
Colussi, G., Catena, C., Novello, M., Bertin, N., & Sechi, L. A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.07.011 · Cited by 182
Huang, Y.-H., Chiu, W.-C., Hsu, Y.-P., Lo, Y.-L., & Wang, Y.-H. (2020) · Nutrients · doi:10.3390/nu12123739 · Cited by 142
“[33] were not considered for meta-analysis due to the lack of numerical data for the functional outcomes in the former and the reporting of only patient-perceived walking performance in the latter.”
BackgroundSo, J., Wu, D., Lichtenstein, A. H., Tai, A. K., Matthan, N. R., Maddipati, K. R., & Lamon-Fava, S. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.018 · Cited by 127
Predicting the effects of supplemental EPA and DHA on the omega-3 index
Walker, R. E., Jackson, K. H., Tintle, N. L., Shearer, G. C., Bernasconi, A., Masson, S., Latini, R., Heydari, B., Kwong, R. Y., Flock, M., et al. (2019) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqz161 · Cited by 93
Self-citation
Metadata
- Authors
- Grenon, S. M., Owens, C. D., Nosova, E. V., Hughes‐Fulford, M., Alley, H. F., Chong, K., Perez, S., Yen, P. K., Boscardin, J., Hellmann, J., Spite, M., & Conte, M. S.
- Venue
- Journal of the American Heart Association
- Published
- 2015-08-25
- Volume
- 4
- Issue
- 8
- Pages
- e002034-e002034
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2152230223
- Cited by
- 84
- References
- 20
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.